- Home
- LUCY vs LGVN Comparison
LUCY vs LGVN Comparison
Compare LUCY & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCY
- LGVN
- Stock Information
- Founded
- LUCY 2017
- LGVN 2014
- Country
- LUCY United States
- LGVN United States
- Employees
- LUCY N/A
- LGVN N/A
- Industry
- LUCY Ophthalmic Goods
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- LUCY Health Care
- LGVN Health Care
- Exchange
- LUCY Nasdaq
- LGVN Nasdaq
- Market Cap
- LUCY 18.5M
- LGVN 30.0M
- IPO Year
- LUCY 2022
- LGVN 2021
- Fundamental
- Price
- LUCY $6.90
- LGVN $2.05
- Analyst Decision
- LUCY Strong Buy
- LGVN Strong Buy
- Analyst Count
- LUCY 1
- LGVN 2
- Target Price
- LUCY $20.00
- LGVN $8.00
- AVG Volume (30 Days)
- LUCY 104.1K
- LGVN 393.9K
- Earning Date
- LUCY 11-12-2024
- LGVN 11-08-2024
- Dividend Yield
- LUCY N/A
- LGVN N/A
- EPS Growth
- LUCY N/A
- LGVN N/A
- EPS
- LUCY N/A
- LGVN N/A
- Revenue
- LUCY $1,529,782.00
- LGVN $1,229,000.00
- Revenue This Year
- LUCY $245.17
- LGVN $161.78
- Revenue Next Year
- LUCY $258.97
- LGVN $8.62
- P/E Ratio
- LUCY N/A
- LGVN N/A
- Revenue Growth
- LUCY 186.54
- LGVN 39.34
- 52 Week Low
- LUCY $3.26
- LGVN $0.77
- 52 Week High
- LUCY $27.20
- LGVN $23.90
- Technical
- Relative Strength Index (RSI)
- LUCY 44.95
- LGVN 52.20
- Support Level
- LUCY $6.33
- LGVN $1.76
- Resistance Level
- LUCY $6.89
- LGVN $2.26
- Average True Range (ATR)
- LUCY 0.59
- LGVN 0.12
- MACD
- LUCY -0.27
- LGVN 0.05
- Stochastic Oscillator
- LUCY 14.46
- LGVN 58.00
About LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products Lucyd Lyte glasses enable the wearer to listen to music, take and make calls, and use voice assistants to perform many common smartphone tasks hands free.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.